Open AccessDeferasirox is a powerful NF- B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging
Author(s) -
Emanuela Messa,
Sonia Carturan,
Chiara Maffè,
Marisa Pautasso,
Enrico Bracco,
Antonella Roetto,
Francesca Messa,
Francesca Arruga,
Ilaria Defilippi,
Valentina Rosso,
Chiara Za,
Antonia Rotolo,
Elisabetta Greco,
Rosa Maria Pellegrino,
Daniele Alberti,
Giuseppe Saglio,
Daniela Cilloni
Publication year - 2010
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2009.016824
Subject(s) - deferasirox , myelodysplastic syndromes , deferiprone , deferoxamine , pharmacology , reactive oxygen species , medicine , cancer research , thalassemia , chemistry , biochemistry , bone marrow
Usefulness of iron chelation therapy in myelodysplastic patients is still under debate but many authors suggest its possible role in improving survival of low-risk myelodysplastic patients. Several reports have described an unexpected effect of iron chelators, such as an improvement in hemoglobin levels, in patients affected by myelodysplastic syndromes. Furthermore, the novel chelator deferasirox induces a similar improvement more rapidly. Nuclear factor-kappaB is a key regulator of many cellular processes and its impaired activity has been described in different myeloid malignancies including myelodysplastic syndromes.